Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Avenzo Therapeutics, Inc.

News headline image
Avenzo Therapeutics Announces Appointment of Scott Lipman as Chief Financial Officer
From Avenzo Therapeutics, Inc.
Via Business Wire
News headline image
Avenzo Therapeutics Granted Fast Track Designation for AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate, for the Treatment of Patients with EGFR-Mutated TKI-Pretreated NSCLC
From Avenzo Therapeutics, Inc.
Via Business Wire
News headline image
Avenzo Therapeutics to Present Initial Results from the Phase 1 Study of AVZO-021, a Potential Best-in-Class CDK2 Inhibitor, at the 2025 San Antonio Breast Cancer Symposium
From Avenzo Therapeutics, Inc.
Via Business Wire
News headline image
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate
From Avenzo Therapeutics, Inc.
Via Business Wire
News headline image
Avenzo Therapeutics Announces $60 Million Series B Financing
From Avenzo Therapeutics, Inc.
Via Business Wire
News headline image
Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-103, a Potential Best-in-Class Nectin4/TROP2 Bispecific Antibody-Drug Conjugate
From Avenzo Therapeutics, Inc.
Via Business Wire
News headline image
Avenzo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class EGFR/HER3 Bispecific Antibody-Drug Conjugate
From Avenzo Therapeutics, Inc.
Via Business Wire
News headline image
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-023, a Potential Best-in-Class, Novel CDK4 Selective Inhibitor
From Avenzo Therapeutics, Inc.
Via Business Wire
News headline image
Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate
From Avenzo Therapeutics, Inc.
Via Business Wire
News headline image
Avenzo Therapeutics Announces FDA Clearance of Investigational New Drug Application for AVZO-023 (ARTS-023), a Potential Best-in-Class, Novel CDK4 Selective Inhibitor
From Avenzo Therapeutics, Inc.
Via Business Wire
News headline image
Avenzo Therapeutics and DualityBio Announce Exclusive Global License for Potential Best-In-Class EGFR/HER3 Antibody-Drug Conjugate
From Avenzo Therapeutics, Inc.
Via Business Wire
News headline image
Avenzo Therapeutics Announces Appointment of Patrick Machado, J.D. to Board of Directors as Independent Director
From Avenzo Therapeutics, Inc.
Via Business Wire
News headline image
Avenzo Therapeutics Provides Corporate Update and Announces Closing of Series A/A-1 Financing
From Avenzo Therapeutics, Inc.
Via Business Wire
News headline image
Avenzo Therapeutics Honored by Goldman Sachs for Entrepreneurship
From Avenzo Therapeutics, Inc.
Via Business Wire
Tickers GS
News headline image
Avenzo Therapeutics Announces Appointment of Garry Nicholson to Board of Directors as Independent Director
From Avenzo Therapeutics, Inc.
Via Business Wire
News headline image
Avenzo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate AVZO-021 and Trodelvy® in HR+/HER2- Metastatic Breast Cancer
From Avenzo Therapeutics, Inc.
Via Business Wire
News headline image
Avenzo Therapeutics Announces $150 Million Oversubscribed Financing To Advance Emerging Oncology Pipeline
From Avenzo Therapeutics, Inc.
Via Business Wire
News headline image
Avenzo Therapeutics Announces Global License of AVZO-021 (ARTS-021), a Potentially Best-in-Class Clinical Stage CDK2 Inhibitor from Allorion Therapeutics
From Avenzo Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.